Full-Time

Marketing Manager

Hepatology

Posted on 8/19/2026

Mirum Pharmaceuticals

Mirum Pharmaceuticals

201-500 employees

ASBT inhibitors for rare liver diseases

No salary listed

Germany

Hybrid

Bachelor's

Category
Growth & Marketing (1)
Required Skills
Market Research
Product Management
Branding/Brand Strategy
Marketing
Data Analysis

Get referred to Mirum Pharmaceuticals

See people who can refer or advise you

Requirements
  • A bachelor's degree in business, marketing, life sciences, or a related field is required.
  • At least 3 years of experience in pharmaceutical marketing, product management, or commercial operations is required, ideally in rare disease.
  • At least 2 years of field and customer-facing experience in pharmaceutical or biotechnology settings is required.
  • Ability to translate global and regional brand strategies into actionable local priorities and initiatives.
  • Ability to work effectively in a matrix organization and build strong relationships across local, regional, and global teams.
  • Strong customer and market orientation, with the ability to translate customer, market, and field insights into marketing initiatives.
  • Strong organizational, project management, and communication skills, with the ability to manage multiple priorities and deadlines.
  • Digital fluency and comfort with digital channels, systems, analytics platforms, and campaign tools.
  • An analytical mindset for synthesizing data and insights, informing decisions, and continuously improving marketing activities.
  • Ability to collaborate effectively across functions in a dynamic, fast-paced environment.
  • Initiative, accountability, and the ability to drive assigned projects forward with a strong focus on execution and results.
Responsibilities
  • Develop and execute German brand and tactical plans for LIVMARLI in collaboration with the General Manager DACH and in alignment with global and regional brand strategies.
  • Translate global and regional brand strategies and initiatives into locally relevant marketing activities adapted to German market needs, customer insights, and regulatory requirements.
  • Work with Regional Marketing and relevant Global teams to ensure alignment, leverage initiatives and best practices, and contribute German market insights to broader brand planning.
  • Develop an understanding of the German hepatology and rare disease landscape, customer needs, patient journey, and competitive environment, and apply these insights to local marketing activities.
  • Develop and implement branded and unbranded marketing initiatives, materials, and field resources across healthcare professional, patient, and digital channels in alignment with strategic objectives and compliance requirements.
  • Support marketing activities and workstreams for the launch readiness of future Hepatology products in collaboration with the General Manager DACH, Regional Marketing, and local cross-functional partners.
  • Collaborate with Medical Affairs, Market Access, Commercial Operations, and Field Teams to align and execute local brand priorities.
  • Manage creative agencies and other external partners, ensuring high-quality, compliant, and timely delivery of marketing initiatives.
Desired Qualifications
  • Experience in pharmaceutical marketing, product management, or commercial operations in rare disease is preferred.
Mirum Pharmaceuticals

Mirum Pharmaceuticals

View

Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases. Its lead drug LIVMARLI (maralixibat) is an oral ASBT inhibitor that lowers bile acid buildup to relieve itching in cholestatic conditions such as Alagille syndrome, and the company is pursuing LIVMARLI for additional rare liver diseases, with volixibat as another ASBT inhibitor in its pipeline. The company differentiates itself by focusing on rare pediatric and adult cholestatic diseases and building dedicated commercialization infrastructure in the U.S. and other major markets, including partnerships with physicians, payers, and patient groups to improve patient access. Mirum’s goal is to bring effective therapies to patients with rare bile-duct and liver disorders, expand LIVMARLI indications, and establish a sustainable market presence in key markets.

Company Size

201-500

Company Stage

IPO

Headquarters

Foster City, California

Founded

2018

Get referred to Mirum Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 net product sales reached $176.2 million, and guidance rose to $680–700 million.
  • FDA granted volixibat Breakthrough Therapy and Orphan Drug designations in August 2026.
  • Brelovitug and volixibat posted positive Phase 2b data, creating multiple 2026–2027 catalysts.

What critics are saying

  • FDA recommended an extra volixibat Phase 3 study in August 2026, delaying PSC filing to H1 2027.
  • Zilurgisertib depends on a September 26, 2026 PDUFA; rejection crushes Mirum’s growth narrative.
  • Mirum’s revenue concentration in LIVMARLI and bile-acid medicines exposes it to payer pressure and competitive erosion.

What makes Mirum Pharmaceuticals unique

  • Mirum dominates rare pediatric cholestasis with LIVMARLI and U.S. commercial infrastructure.
  • Mirum pairs approved liver drugs with a late-stage rare-disease pipeline and regulatory assets.
  • Mirum licensed zilurgisertib from Incyte; FDA accepted the NDA for September 26, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
CNBC TV18
Aug 20th, 2026
US FDA approves Regeneron's rare bone disorder drug.

US FDA approves Regeneron's rare bone disorder drug. Regeneron's Pasatru has received US FDA approval for adults with FOP after clinical trials showed a significant reduction in abnormal bone formation. By Reuters August 20, 2026, 8:59:40 AM IST (Published) The US FDA on Wednesday (August 19) approved Regeneron's drug for a rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues. New York-based Regeneron's shares rose 4%. The drug, garetosmab, branded as Pasatru, was approved to treat adults with fibrodysplasia ossificans progressiva (FOP) - a condition in which muscle, tendon and ligament tissue gradually turns into bone, leading to a "second skeleton" that causes progressive loss of mobility and reduced life expectancy. In a 56-week trial involving 63 participants, Pasatru reduced the development of new bone abnormalities by 94% in patients treated with a 3 mg per kg dose and by 90% in those given a 10 mg per kg dose, compared with a placebo. The drug works by blocking Activin A, a protein involved in triggering abnormal bone growth in patients with FOP. Susan Rhee, a member of Regeneron's clinical team, told Reuters last week that the company plans to start a trial for children later this year. The drug will compete with French drugmaker Ipsen's oral treatment Sohonos, which in 2023 became the only other treatment approved by the US Food and Drug Administration. Incyte and partner Mirum Pharma, as well as privately held Ashibio, are also developing treatments for the condition. In 2020, Regeneron paused dosing in a mid-stage trial of the drug after five patient deaths, ultimately discontinuing the study and working with global regulators to design the late-stage trial, according to the company. The condition affects roughly 1 in 2 million people worldwide, with around 800 to 900 active diagnosed cases globally, according to data from the National Institutes of Health.

Yahoo Finance
Aug 6th, 2026
FDA requests Phase 3 trial for Mirum's Volixibat, delaying NDA until H1 2027 — MIRM stock crashes 15%

Mirum Pharmaceuticals shares plunged 15% on Thursday after the FDA recommended an additional Phase 3 study for its liver disease candidate Volixibat, potentially delaying the new drug application until the first half of 2027. Citizens lowered its price target to $137 from $146 whilst maintaining an Outperform rating. The regulatory setback overshadowed strong second-quarter results. Mirum reported revenue of $176.2 million, beating analysts' estimates of $167.3 million. The company raised its full-year net product sales guidance to $680 million to $700 million, from $660 million to $680 million. Mirum ended the quarter with $561.3 million in cash and equivalents. Volixibat has already received FDA Breakthrough Therapy and Orphan Drug designations.

Yahoo Finance
Aug 6th, 2026
Mirum raises 2026 guidance to $700M, delays PSC drug filing amid FDA review

Mirum Pharmaceuticals raised its full-year 2026 net product sales guidance to $680 million to $700 million, citing growth in Alagille syndrome and expanding adult PFIC diagnosis. The company secured $690 million through a convertible note offering, improving its capital structure whilst settling 75% of 2029 notes. The firm identified a significant opportunity in adult PFIC, estimating at least 2,000 addressable patients each in the US and Europe. Commercial operations achieved a high-50s percent cash contribution margin, representing a 5 percentage point year-over-year improvement. Mirum delayed its volixibat PSC NDA submission due to alignment issues with FDA reviewers but received Breakthrough Therapy Designation. The company targets a first-half 2027 NDA submission for PSC and anticipates Phase III PBC results in Q1 2027.

Yahoo Finance
Aug 6th, 2026
Mirum Pharmaceuticals' Q2 revenue hits $176M, up 38% year-on-year despite widened loss

Mirum Pharmaceuticals reported revenue of $176.24 million for the quarter ended June 2026, up 37.9% year-over-year. The figure exceeded the consensus estimate of $164.76 million by 6.97%. The company posted a loss of $0.80 per share, compared to $0.12 a year ago, slightly missing the estimated loss of $0.77 per share. Product sales showed strong performance across categories. Livmarli generated $128.72 million, surpassing the $119.6 million analyst estimate. Bile acid medicines brought in $47.52 million, also beating expectations of $45.64 million. Despite beating revenue estimates, Mirum's shares fell 18.7% over the past month, underperforming the S&P 500's 3.5% gain.

Investing.com
May 13th, 2026
Mirum prices $600m convertible notes offering due 2032 By Investing.com

Mirum prices $600m convertible notes offering due 2032